PROPOFOL (PROPOFOL)
- Administration of general anesthesia
- General anesthesia adjunct
- Sedation in intubated patient
- Sedation as adjunct to anesthesia
10 mg/mL intravenous emulsion
- Dosage information is not available
10 mg/mL intravenous emulsion
- Dosage information is not available
Sedation in intubated patient
- Infuse 5 mcg/kg/minute by continuous infusion route
- Infuse 50 mcg/kg/minute by continuous infusion route
- artemether-lumefantrine
- Coartem
- disopyramide
- dronedarone
- droperidol
- Multaq
- Norpace
- Norpace Cr
- Orap
- pimozide
Contraindicated
- amiodarone
- amiodarone in dextrose,iso-osm
- Avelox
- Avelox Abc Pack
- Avelox In Nacl (iso-osmotic)
- Caprelsa
- Cordarone
- dofetilide
- Fareston
- Geodon
- Invega
- Invega Sustenna
- Invirase
- Kaletra
- lopinavir-ritonavir
- moxifloxacin
- moxifloxacin in NaCl (iso-osm)
- Nexterone
- nilotinib
- Pacerone
- paliperidone
- paliperidone palmitate
- propafenone
- Qualaquin
- quetiapine
- quinine sulfate
- Rythmol
- saquinavir mesylate
- Seroquel
- Seroquel Xr
- sodium oxybate
- Tasigna
- tetrabenazine
- thioridazine
- Tikosyn
- toremifene
- vandetanib
- Xenazine
- Xyrem
- ziprasidone HCl
- ziprasidone mesylate
Severe
Moderate
- Abstral
- Actiq
- alfuzosin
- Anzemet
- Apokyn
- apomorphine
- clozapine
- Clozaril
- Complera
- dasatinib
- dolasetron
- Duragesic
- Edurant
- emtricitab-rilpivirine-tenofov
- Fazaclo
- fentanyl
- fentanyl citrate
- fentanyl citrate (PF)
- Fentora
- lapatinib
- Lazanda
- norfloxacin
- Noroxin
- Noxafil
- pasireotide
- pazopanib
- posaconazole
- rilpivirine
- Signifor
- Sprycel
- Sublimaze (pf)
- Subsys
- Tykerb
- Uroxatral
- Versacloz
- Votrient
- None
Contraindicated
- Pancreatitis
Severe
Moderate
- Cerebral arteriosclerosis
- Debilitation
- Hyperprolinemia
- Hypotension
- Hypovolemia
- Seizure disorder
PROPOFOL (PROPOFOL)
- Administration of general anesthesia
- General anesthesia adjunct
- Sedation in intubated patient
- Sedation as adjunct to anesthesia
- Apnea
- Bradycardia
- Hypotension
- Injection site sequelae
More Frequent
Severe
Less Severe
- Hyperlipidemia
- Hypertension
- Leukocytosis
- Opisthotonus
- Skin rash
- Pruritus of skin
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal ECG
- Abnormal hepatic function tests
- Acute renal failure
- Anaphylaxis
- Angioedema
- Atrial fibrillation
- Atrioventricular block
- Bronchospastic pulmonary disease
- Cardiac arrest
- Dyspnea
- Extrasystoles
- Heart failure
- Hemorrhage
- Hepatomegaly
- Hyperkalemia
- Hypertonia
- Hyperventilation
- Hypomagnesemia
- Hypoventilation
- Hypoxia
- Metabolic acidosis
- Perioperative myoclonia
- Priapism
- Respiratory depression
- Respiratory obstruction
- Rhabdomyolysis
- Right ventricular failure
- Seizure disorder
- Venous thrombosis
- Ventricular premature beats
- Ventricular tachycardia
Less Severe
- Abdominal pain with cramps
- Acquired dystonia
- Agitation
- Chills
- Cloudy urine
- Conjunctival hyperemia
- Cough
- Diarrhea
- Dizziness
- Drowsy
- Erythema
- Fever
- Flushing
- Headache disorder
- Hiccups
- Ileus
- Myalgias
- Nausea
- Ocular hypotony
- Oliguria
- Phlebitis after infusion
- Sialorrhea
- Urinary retention
- Urine discoloration
- Urticaria
- Vomiting
- Xerostomia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Propofol
Risk of apnea and long-term cognitive deficit for duration of use exceeding 3 hours.
- 1 Day – 3 Years
- Risk of apnea and long-term cognitive deficit for duration of use exceeding 3 hours.
Propofol
- Severity Level:
2
- Additional Notes: Insuff human data available
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Propofol
Limited data suggest amount excreted is minimal
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Excreted | Not known; no or inclusive data | Limited data suggest amount excreted is minimal |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
Propofol
General-Increasing patient age results in higher peak plasma levels. To reduce the risk for cardiorespiratory depression, use lower doses of 1-1.5 mg/kg for induction. Avoid rapid bolus administration.
Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
Increased Risk / Adverse Effects | N | N | Y | N | Y | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None